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The value of carotid endarterectomy (CEA) in
the treatment of both symptomatic and asympto-
matic carotid occlusive disease has been demonstrat-
ed in randomized trials.1-3 In these trials, researchers
documented a statistically significant lower long-term
stroke rate in the surgical groups versus patients
receiving only medical therapy. Extrapolating the
results from these trials to the general population of
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patients and surgeons requires some caution. The
randomized trials excluded patients with comorbid
conditions that would be associated with high surgi-
cal mortality and low long-term survival. Surgeons
accepted for participation in the trials had to have
documentation of patients with combined stroke or
mortality rates that were deemed acceptable. Neither
of these conditions are necessarily true for the entire
population of patients undergoing CEA. Despite
calls by vascular surgery leadership to focus on the
results of procedures, many surgeons performing
CEAs are unaware of their patients’ stroke or mor-
tality rates.4-5 In some contemporary community-
wide outcome studies, there have been reports of
combined stroke or mortality rates similar to those
achieved in the randomized trials, although many of
these studies have been limited by relying on either
administrative data or voluntary reporting.6-15
We developed a project to document the statewide
outcomes of CEA and distribute confidential institu-
tion-specific outcome and care process reports to sur-
geons and hospital staff. Opportunities for discussion
of outcome and process variation with surgeons from
multiple institutions were provided. Institutions were
recruited for a voluntary effort of ongoing data collec-
tion for CEA to facilitate continuous quality improve-
ment. Outcome and process results over time, as well
as comparison data, were provided to each of these
participating institutions. This report details the results
of the quality improvement effort.
METHODS
The Iowa Foundation for Medical Care (IFMC)
is the Medicare peer review organization for Iowa.
In 1992, the Health Care Financing Administration
(HCFA) implemented the Health Care Quality
Improvement Program.16 This new initiative en-
couraged the use of quality improvement principles
to improve health care for Medicare beneficiaries. As
part of the health care quality improvement pro-
gram, the IFMC has been performing statewide
quality improvement activities for specific clinical
topics affecting the Medicare population.
Data collection. In 1995 a project focusing on
the outcomes of CEA was initiated. Iowa Medicare
claims files were used to identify all CEA procedures
performed on Medicare patients who were dis-
charged between January 1, 1994, and December
31, 1994. All Medicare hospital claims (MEDPAR
Part A) with a procedure code of 38.12 (endarterec-
tomy of vessels of head and neck) from the
International Classification of Diseases-ninth revi-
sion-Clinical Modification were selected. In addi-
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tion, the Medicare Part B files (physician bills) were
used to identify all Current Procedural Terminology
(CPT) procedure codes of 35301. The Part A claims
were also used to obtain all hospital readmissions
within 30 days for the patients who were identified
as having a CEA performed. The Medicare benefi-
ciary data set was used to identify any deaths that
occurred within 30 days of the procedure.
A data collection tool was created for medical
record abstraction by trained abstractors. Inform-
ation was obtained from each medical record regard-
ing patient demographics, indication for the proce-
dure, perioperative care processes, and postoperative
outcomes. Chart review was carried out for both the
index hospitalization and any readmissions within 30
days.
A second statewide data collection with central-
ized abstraction was carried out for all Medicare
patients who underwent CEA in Iowa between
June 1, 1995, and May 31, 1996, including hospi-
tal readmissions within 30 days and linkage with the
Medicare beneficiary data set for postdischarge
death. The third data collection period reported in
this study was from hospitals that chose to partici-
pate in ongoing data collection using the Project-
in-a-Box methodology described later. Although
this data set includes all patients undergoing the
procedure, only the Medicare subset is reported to
allow comparison to the earlier time periods. The
PIB data collection focused on the initial hospital-
ization, so only in-hospital complication rates are
available. Further details on the second and third
data collection periods, including processes to
ensure reliability and validity, are provided in an
appendix available on the web version of this manu-
script.
Definitions. Indications for CEA were classified
into four categories. Patients were considered to
have stroke as the indication for the procedure only
if they had documented ipsilateral hemispheric
symptoms that persisted for more than 24 hours
within 90 days before the procedure. Similarly,
patients were considered to have transient ischemic
attack (TIA) as the indication only if transient ipsi-
lateral hemispheric symptoms occurred within 90
days before the procedure. Patients were considered
to be asymptomatic only if there was no history at
any time before the procedure of cerebrovascular
symptoms or events in either the anterior or posteri-
or circulations. All other patients (eg, those with
remote symptoms, global or vertebrobasilar symp-
toms, contralateral hemispheric symptoms) were
classified in a nonspecific category. These definitions
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were used to create relatively clean indication groups
of stroke, TIA, and asymptomatic with high repro-
ducibility given the limitations of retrospective med-
ical record review.
The CEA procedures were classified into three
procedure groups. A CEA with coronary artery
bypass grafting (CABG) included patients who had
both CEA and CABG during the same operative
episode. A CEA reoperation was used for patients
who had a prior ipsilateral CEA. All other patients
were included in a CEA-alone group. This report is
confined to the CEA-alone subgroup.
For the purpose of outcome classification, a post-
operative stroke was considered to have occurred if
any new or worsening central nervous system deficit
developed either during the hospitalization (in-hos-
pital) or within 30 days after the procedure (30 day)
and persisted for more than 24 hours. Postoperative
strokes were classified as major or minor by looking
at a point in time 5 days after the stroke, or on the
day of hospital discharge, whichever occurred soon-
er. If patients had a new persistent deficit that result-
ed in a need for assistance with ambulation or eating
or if patients had a new persistent aphasia, they were
considered to have had a major stroke. Patients with-
out disability were considered to have had a minor
stroke. These relatively simple definitions allowed for
reproducible classification by nurse abstractors using
information typically available in the medical record.
Deaths were considered stroke related if the death
was associated with a major stroke. If there was no
evidence of a major stroke associated with the death,
the death was classified as nonstroke related.
Quality improvement interventions. The
statewide outcomes of CEA (major strokes, minor
strokes, other complications and deaths) in the state
were stratified by the hospital. Hospital representatives
were provided confidential reports on the outcomes
and perioperative care processes for the procedure at
their institution as well as statewide comparisons.
Surgeons were invited to meetings to discuss the 
outcome data as well as perioperative care process vari-
ation. The actual medical records for patients classified
as having postoperative strokes were available for 
confidential review by surgeons from the involved
institutions.
Participation was solicited in a project of volun-
tary ongoing monitoring of care processes and out-
comes using trained abstractors at each hospital. The
PIB, a self-contained set of monitoring tools and
intervention strategies, had been developed for sev-
eral clinical conditions, including CEA, by the
IFMC. The IFMC provides the data-collection tool,
training of abstractors, data validation, and periodic
feedback reports with institutional and statewide
comparison data for each project. A total of 14 hos-
pitals are participating in the CEA PIB ongoing
data-collection process in Iowa. The significance of
differences between time periods was evaluated
using the Mantel-Haenzel χ2 test with one degree of
freedom (Centers for Disease Control and Pre-
vention’s Epi Info Version 6).
RESULTS
Table I displays the demographic and outcome
data from the statewide data collection periods in
1994 and 1995 to 1996. In 1994 there were 798
CEA-alone procedures performed on Medicare
patients in Iowa. These procedures were performed
in 29 hospitals by 78 different surgeons. The com-
bined stroke or mortality rate for these procedures
was 7.8%. During this time period 20% of the pro-
cedures were performed on asymptomatic patients.
During the 12-month period from 1995 to 1996,
there were 1265 CEA-alone procedures performed
on Medicare patients, an increase of 59%. During
this time period, 79 different surgeons performed
the procedure in 30 hospitals. The proportion of
patients who were asymptomatic increased to 40%.
The overall combined stroke or mortality rate was
4.0%. This drop (7.8% to 4.0%, P < .001) was only
partially accounted for by the increased number of
asymptomatic patients in the 1995 to 1996 period.
The in-hospital combined stroke or mortality rate in
patients with specific or nonspecific symptoms
dropped from 9.1% to 4.6% (P < .001) between
1994 and 1995 to 1996. The overall mortality rate
fell from 2.9% in 1994 to 1.1% (P = .003) during the
time period of 1995 to 1996, and the nonfatal
stroke rate decreased from 4.9% to 2.8% (P = .05).
The median age of the patients (74 years) was
unchanged in both 1994 and 1995 to 1996.
Table II provides a comparison of the in-hospital
with 30-day morbidity/mortality results from the
statewide 1994 and 1995 to 1996 data collection
periods. The in-hospital combined stroke or mortal-
ity rate was 7.8% in 1994. Morbidity and mortality
data obtained from the readmission record abstrac-
tion and HCFA beneficiary file for deaths indicated
an 8.8% 30-day combined stroke or mortality rate
for the same patient group. In the data period of
1995 to 1996, the in-hospital combined stroke or
mortality rate was 4.0%, whereas the 30-day rate was
5.3%. During 1994 there was only one postdis-
charge death that occurred within the 30-day peri-
od. In 1995 to 1996, the postdischarge deaths
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resulted in an increase in the mortality rate from
1.1% in-hospital to 1.7% at 30 days.
Table III displays the demographic and outcome
data for Medicare patients from the 14 PIB hospitals
during the three measurement periods. The 14 hos-
pitals accounted for 550 (64%) of Iowa Medicare
CEA procedures in 1994 and 938 (74%) of the Iowa
cases during the 1995 to 1996 period. In the 12-
month time period from June 1, 1997, to May 31,
1998, these hospitals reported 843 CEA-alone pro-
cedures. The median age of the patients in this time
period was 74 years, and the proportion of patients
who were asymptomatic was 46%. The combined in-
hospital stroke or mortality rate dropped significant-
ly in the 14 participating hospitals from 6.5% (1994)
to 3.7% (1995-1996) to 1.8% (1997-1998) (1994
to 1995-1996, P = .014; 1995-1996 to 1997-1998,
P = .013). The mortality rate decreased from 2.4%
(1994) to 1.3% (1995-1996) to 0.6% (1997-1998)
(1994 to 1997-1998, P = .004). The change in mor-
tality from the 1995 to 1996 time period to the
1997 to 1998 time period was entirely due to the
absence of stroke-related mortality in the latter time
period. The stroke-related mortality was 0.7% in
1995 to 1996 and 0% in 1997 to 1998, whereas
nonstroke mortality was 0.5% in 1995 to 1996 and
0.6% in 1997 to 1998. The major (disabling) stroke
rate decreased from 3.1% (1994) to 1.7% (1995-
1996) to 0.7% (1997-1998) (1994 to 1997–1998,
P < .001). Although the percentage of patients who
were asymptomatic increased dramatically between
1994 and 1995 to 1996 (22% and 40%), the trend
leveled off, and the percentage of asymptomatic
patients was 46% during the most recent time 
period.
Table IV provides the process data from the PIB
hospitals during the three study time periods. There
were significant care process changes occurring over
the course of the study that may have influenced the
improvement in outcomes from the baseline period.
The proportion of patients receiving preoperative
antiplatelet therapy with aspirin or ticlopidine
increased from 66% in 1994 in the participating hos-
pitals to 72% in 1997 to 1998 (P = .02). The per-
centage of procedures performed without cerebral
monitoring or routine shunting decreased from 30%
in 1994 to 24% in 1997-1998 (P = .011). In 1994,
14% of the patients received a patch closure. Patch
angioplasty (both vein and prosthetic) use increased
to 30% in 1997-1998 (P < .001). In 1994 only 20%
of the patients had a documented intraoperative,
postreconstruction evaluation of the operative site
with angiography, B-mode ultrasound scanning, or
Doppler scanning. These modalities were used in
46% of the patients in 1997-1998 (P < .001).
Protamine reversal of heparin was used in 65% of
cases in 1994 and 56% of cases in 1997-1998 
(P < .001).
Table I. CEA (CEA alone) demographics and in-hospital outcomes—statewide
Statewide (29 hospitals) Statewide (30 hospitals)
Jan 1994–Dec 1994 Jun 1995–May 1996
Total no. of CEA-alone procedures 798 1265
Total no. of CEA-alone patients 726 1160
Median age (y) 74 74
Percent male 60% 59%
Percent asymptomatic 20% 40%
Combined stroke or mortality rate 7.8% (62/798) 4.0%* (50/1265) 
By indication
Ipsilateral stroke 6.3% (6/96) 7.0% (9/128)
Ipsilateral TIA 10.8% (21/194) 4.3%* (8/184)
Nonspecific 8.9% (31/349) 4.1%* (18/441)
Asymptomatic 2.5% (4/159) 2.9% (15/512)
Mortality rate 2.9% (23/798) 1.1%* (14/1265)
Stroke related 1.1% (9/798) 0.7% (9/1265)
Nonstroke related 1.8% (14/798) 0.4%* (5/1265)
Nonfatal stroke rate 4.9% (39/798) 2.8%* (36/1265)
Major 3.4% (27/798) 2.0%* (25/1265)
Minor 1.5% (12/798) 0.9% (11/1265)
*A statistically significant difference from 1994 (P < .05).
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DISCUSSION
The baseline data obtained in 1994 indicated that
the morbidity and mortality for CEA in the Medicare
population in Iowa was somewhat higher than was
achieved in the randomized trials. The 30-day com-
bined stroke or mortality rate in the 1994 sympto-
matic (stroke and TIA) patients was 10%, and in the
asymptomatic patients it was 3.8%. The overall 30-
day combined stroke or mortality rate in the North
American Symptomatic Carotid Endarterectomy
Trial (NASCET) (combined reports) was 6.5%.1,2
The 30-day combined stroke or mortality rate in the
Asymptomatic Carotid Atherosclerosis Study
(ACAS) was 1.5% (excluding strokes reported for the
intention of treating analysis that actually occurred
preoperatively).3 The overall CEA 30-day mortality
rate for Medicare patients in Iowa in 1994 was 2.9%.
The mortality rate in the NASCET was 1.0% and
0.1% in the ACAS.1-3 Although the Medicare popu-
lation is older and included patients with comorbid
conditions that would have met exclusion criteria for
entry in the randomized trials, the higher morbidity
and mortality reduce the purported benefit of surgi-
cal therapy over medical therapy.
There were a number of other community-wide
outcome studies focusing on CEA procedures per-
formed since 1990. The studies vary in methodology,
and comparisons are often difficult.15 Researchers
relying on administrative databases (claims or dis-
charge data) are often unable to categorize patients by
indication, and reporting of complications may be
incomplete.6-8 Voluntary registries can be limited only
because of the inclusion of data from select surgeons
(eg, vascular society registries) or because of reporting
bias.12-14 In recent studies where chart review was
used, researchers have generally reported overall com-
bined stroke or mortality rates in the 5% to 6%
range.9-11
The major goal of our project was to see if a
statewide quality improvement effort could result in a
reduction in the surgical morbidity and mortality. A
cornerstone of quality improvement is measurement.
An initial step was the development of the tools that
would allow measurement at the individual provider
level to track progress over time and allow peer com-
Table II. CEA outcomes—statewide (in-hospital vs 30-day)
In-hospital 30-day
Iowa 1994 (n = 29)
Combined stroke or mortality rate 7.8% (62/798) 8.8% (70/798)
Ipsilateral stroke 6.3% (6/96) 7.3% (7/96)
Ipsilateral TIA 10.8% (21/194) 11.3% (22/194)
Nonspecific 8.9% (31/349) 9.7% (34/349)
Asymptomatic 2.5% (4/159) 3.8% (6/159)
Mortality rate 2.9% (23/798) 3.0% (24/798)
Stroke related 1.1% (9/798) 1.3% (10/798)
Nonstroke related 1.8% (14/798) 1.8% (14/798)
Nonfatal stroke rate 4.9% (39/798) 5.8% (46/798)
Major 3.4% (27/798) 3.9% (31/798)
Minor 1.5% (12/798) 1.9% (15/798)
Iowa 1995-1996 (n = 30)
Combined stroke or mortality rate 4.0% (50/1265) 5.3% (67/1265)
Ipsilateral stroke 7.0% (9/128) 10.9% (14/128)
Ipsilateral TIA 4.3% (8/184) 6.5% (12/184)
Nonspecific 4.1% (18/441) 5.4% (24/441)
Asymptomatic 2.9% (15/512) 3.3% (17/512)
Mortality rate 1.1% (14/1265) 1.7% (21/1265)
Stroke related 0.7% (9/1265) 0.9% (11/1265)
Nonstroke related 0.4% (5/1265) 0.8% (10/1265)
Nonfatal stroke rate 2.8% (36/1265) 3.6% (46/1265)
Major 2.0% (25/1265) 2.3% (29/1265)
Minor 0.9% (11/1265) 1.3% (17/1265)
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parison. Although there is a strong evidence base (the
randomized controlled trials) for the expected out-
come measures, the evidence base for many of the
CEA process measures, with the possible exception of
antiplatelet therapy, is lacking.17 Our approach was to
report the process measures that may result in better
outcomes (eg, intraoperative monitoring of cerebral
perfusion to determine the need for shunting; intraop-
erative, postreconstruction assessment of the operative
site; use of patch angioplasty) without using these
measures as quality indicators per se.
The key risk adjustment variable for comparison
of CEA outcomes is the symptom status of the
patient. Any retrospective, medical record abstrac-
tion-based project has limitations with respect to
categorization of patients. In addition to the scarce
documentation found in some medical records,
terms such as transient ischemic attack or stroke are
often used in a nonspecific manner. We chose to
define strict categories of stroke, TIA, and asympto-
matic with classification of all other patients in a
nonspecific category. This allowed comparison to
the benchmarks achieved in the randomized trials
for the symptomatic and asymptomatic patients.
Patients were categorized as having TIA or stroke as
an indication for the procedure only if they had
recent (< 90 days) ipsilateral, hemispheric symptoms
or imaging evidence, in the case of stroke. Patients
with remote, contralateral, or posterior circulation
symptoms were included in the nonspecific catego-
ry. For example, patients with contralateral or poste-
rior circulation symptoms and an occluded con-
tralateral carotid are likely to have a higher surgical
risk than completely asymptomatic patients,
although strictly speaking, the ipsilateral carotid ter-
ritory is asymptomatic. In our data set this type of
patient was included in the nonspecific category.
Despite our strict definition of asymptomatic, the
asymptomatic group accounted for almost half of
the patients undergoing CEA in the most recent
time period. Our asymptomatic group should have
had a stroke risk at least the same as, if not lower
than, a group of patients with the asymptomatic
hemisphere definition.
The importance of risk adjustment of the com-
bined stroke or mortality rate based on indication is
illustrated in comparing the statewide results in the
1994 and 1995 to 1996 time periods. The number of
cases markedly increased by 59% between these two
periods. Only 5% of this increase was in patients with
TIA or stroke as the indication for the procedure. The
increase was almost certainly related to the publication
of the results of the ACAS, and 75% of the increase was
in patients in the asymptomatic category. As expected,
the combined stroke or mortality rate in the asympto-
matic patients was lower than in those with specific or
Table III. CEA demographics and in-hospital outcomes: participating hospitals (n = 14)
Jan 1994–Dec 1994 Jun 1995–May 1996 Jun 1997–May 1998
Total no. of CEA-alone procedures 550 938 843
Total no. of CEA-alone patients 504 869 787
Median age (y) 73 74 74
Percent male 61% 59% 62%
Percent asymptomatic 22% 40% 46%
Combined stroke or mortality rate 6.5% (36/550) 3.7%* (35/938) 1.8%*† (15/843)
By indication
Ipsilateral stroke 7.1% (5/70) 6.4% (6/94) 4.2% (3/72)
Ipsilateral TIA 8.5% (11/130) 4.5% (6/133) 3.9% (5/128)
Nonspecific 8.2% (19/231) 2.7%* (9/332) 1.6%* (4/253)
Asymptomatic 0.8% (1/119) 3.7% (14/379) 0.8%† (3/390)
Mortality rate 2.4% (13/550) 1.3% (12/938) 0.6%* (5/843)
Stroke related 1.1% (6/550) 0.7% (7/938) 0.0%* (0/843)
Nonstroke related 1.3% (7/550) 0.5% (5/938) 0.6% (5/843)
Nonfatal stroke rate 4.2% (23/550) 2.5% (23/938) 1.2%*†(10/843)
Major 3.1% (17/550) 1.7% (16/938) 0.7%*(6/843)
Minor 1.1% (6/550) 0.7% (7/938) 0.5% (4/843)
*A statistically significant difference from 1994 (P < .05).
†A statistically significant difference from 1995-1996 (P < .05).
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nonspecific symptoms, and the changes in indication
distribution alone would be expected to result in an
overall decreased morbidity/mortality. Because the
outcomes could be stratified by indication, it was
noted that the marked decrease in combined stroke or
mortality rate between 1994 and 1995 to 1996 was
not solely due to a rise in the proportion of asympto-
matic patients (Tables I and III). This is illustrated by
the decrease in the combined stroke or mortality rate
from 9.1% to 4.6% in the patients with specific and
nonspecific symptoms.
Record review was necessary for accurate determi-
nation of the complications, in addition to providing
the necessary data for risk adjustment. Although the
HCFA beneficiary file is an accurate source of informa-
tion about mortality and is useful in tracking postdis-
charge mortality, administrative claims data are not
accurate regarding the documentation of the occur-
rence of postoperative strokes. The stroke codes are
sometimes used for both preoperative and postopera-
tive events, and many postoperative strokes are not
reflected in claims data. Our medical record review also
allowed some measure of the severity of the postopera-
tive stroke. The simple definition of major stroke (new
or worsening difficulty with walking or eating, which
results in the need for assistance, or difficulty commu-
nicating, at 5 days after the event) allowed reproducible
categorization from information available in most med-
ical records. More complex stroke scales would only be
useful in prospective data collection. The use of chart
abstraction also allowed us to collect care process infor-
mation (use of antiplatelet agents, intraoperative mon-
itoring of cerebral perfusion, patching, reversal of
heparin, postreconstruction assessment) that would not
be available from administrative data.
The ongoing hospital-based PIB data collection
effort focused on in-hospital outcomes. Obtaining
30-day outcomes is difficult using hospital-based
abstraction because patients with complications may
not always return to the same institution. Obviously,
in-hospital and 30-day outcomes should not be
compared, but it is our opinion that in-hospital out-
comes are useful for peer and longitudinal compari-
son. Most adverse outcomes occur before hospital
discharge, as was demonstrated in our statewide data
collection periods (Table II).
A criticism of the onsite data collection method-
ology used for PIB is the theoretical possibility of
selective or altered reporting by providers. We
believe this possibility has been minimized first and
foremost by the confidential, quality improvement
focus of this effort as opposed to efforts involving
public disclosure and accountability. The New York
Coronary Artery Bypass Study is an example of an
accountability effort that may have contributed to
an overall decline in CABG procedural morbidity
and mortality in that state.18 This public disclosure
approach also created a strong incentive for
Table IV. CEA processes: participating hospitals (n = 14)
Jan 1994-Dec 1994 Jun 1995-May 1996 Jun 1997-May 1998
Antithrombotic therapy
Preoperative aspirin or ticlopidine 65.8% (362/550) 69.5% (652/938) 71.9%* (606/843)
Intraoperative heparin 99.5% (547/550) 98.5% (924/938) 98.7% (832/843)
Heparin with protamine 65.4% (358/547) 52.2%* (482/924) 56.4%* (469/832)
Monitoring of cerebral perfusion
Local/regional anesthesia 21.3% (117/550) 24.4% (229/938) 18.7%† (158/843)
EEG 30.7% (169/550) 32.7% (307/938) 25.4%*† (214/843)
Back pressure 8.0%  (44/550) 9.1% (85/938) 14.1%*† (119/843)
Transcranial Doppler scan 0.0% (0/550) 0.1% (1/938) 6.5%*† (55/843)
Shunt, no monitoring 20.2% (111/550) 18.1% (170/938) 20.9% (176/843)
No shunt, no monitoring 29.8% (164/550) 27.3% (256/938) 23.7%* (200/843)
Patch grafting
Vein 10.7% (59/550) 1.4%* (13/938) 1.8%* (15/843)
Prosthetic 3.5% (19/550) 12.0%*(113/938) 28.4%*† (239/843)
Postreconstruction assessment
Angiogram 0.5% (3/550) 0.7% (7/938) 0.0%*† (0/843)
Ultrasound image/duplex scan 4.2% (23/550) 4.6% (43/938) 6.0% (51/843)
Doppler scan 14.9% (82/550) 23.5% (220/938) 39.6%*† (334/843)
*A statistically significant difference from 1994 (P < .05).
†A statistically significant difference from 1995-1996 (P < .05).
EEG, Electroencephalogram.
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providers to avoid high-risk patients and possibly
“game the system” by overestimating risk variables.
Our approach to improving outcomes was more in
line with the model of the Northern New England
Cardiovascular Diseases Study Group.19 Because the
focus in our study was on quality improvement with
discussion of process differences by surgeons, but
confidential outcomes data release, the incentive for
selective or altered reporting is reduced. Another
advantage of a quality improvement versus an
accountability approach to outcomes analysis is the
ability to provide useful information with smaller
denominators. If this project were designed for
accountability or public disclosure, the large num-
bers required to have statistical assurance that indi-
vidual reported rates are valid estimates of the true
complication rates would not have been achieved for
many surgeons and hospitals in this project.
There were significant improvements in out-
comes seen during the course of our study, which
were documented in both the overall statewide sam-
ple and the hospitals participating in the PIB. The
outcome improvements were seen in all indication
categories. We believe that the improvements were
related to the feedback of the data, in addition to
peer discussion of the process and outcome results.
Local feedback of data in this fashion has been
shown to alter physician behavior even when cor-
rected for national trends.20 We also identified sig-
nificant changes in many of the process measures
over the course of the study, with the increases in
patching and intraoperative assessment of the opera-
tive site being the most dramatic. Obviously, this
type of retrospective study cannot determine the
relationship between those process measures and the
improved outcomes. It is possible that other factors
may explain some of the improvement that
occurred. Patient selection and/or changing referral
or practice patterns likely also play a role.
CONCLUSIONS
The results reported in this study suggest that
confidential feedback of outcome and process data
for CEA may lead to changes in process and
improved outcomes. It is our opinion that outcome
measurement is best accomplished with a quality
improvement approach rather than with an account-
ability/public disclosure effort. We believe that it is
incumbent on every surgeon performing CEA to
participate in some form of standardized outcome
assessment. Surgeon and hospital level outcome
analysis is necessary to ensure that optimum results
are being achieved.
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throughout the project. The strokes were also vali-
dated by two physician reviewers. Disagreements
were arbitrated by the lead author (TFK). In addition
to the patients identified as having postoperative
strokes, a subset of patients classified as having no
postoperative stroke was subject to the same valida-
tion process. The subset chosen was based on admin-
istrative characteristics (hospital length of stay > 5
days, discharge codes suggesting postoperative neu-
rologic complications, and discharge other than to
home) that had been shown to be associated with
postoperative strokes. The PIB data used included all
CEA patient discharges from the 14 participating
hospitals in the 12 months between June 1, 1997,
and May 31, 1998. The first 15 records submitted
from each institution were reabstracted by IFMC
nurse abstractors to validate the on-site abstraction
and to facilitate training of the hospital-based
abstractors. All strokes identified during this time
period were validated by SLG, MAB, and TFK.
APPENDIX
The second data collection period in Iowa (June
1995-May 1996) was part of a HCFA-sponsored 10-
state CEA quality improvement effort led by the
IFMC. A data collection tool was developed by the
IFMC using the definitions from the original project.
Medicare Part A claims files were used to identify
patients with a procedure code of 38.12 from the
International Classification of Diseases-ninth revi-
sion-Clinical Modification discharged between June
1, 1995, and May 31, 1996. In Iowa, all Medicare
patients meeting these criteria during that 12-month
time period were selected for analysis. The records
were reviewed initially by trained abstractors at a
HCFA Clinical Data Abstraction Center
(DynKePRO, York, Penn). All Iowa patients desig-
nated as having strokes were reviewed by two nurse
reviewers (SLG, MAB), who led the data collection
tool development and abstractor training efforts
